Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Jai Ho

Rakesh Jhunjhunwala’s Latest Blue-Chip Small-Cap Stock Pick Is On Verge Of “Multiple Year Break Out”: Experts



rakesh jhunjhunwala tata comm

Rakesh Jhunjhunwala has recently invested in a blue-chip small-cap stock of impeccable credentials. Experts have opined that the stock is poised for a “multiple year break out” and is a must-buy

How Could Eros Intl Make A Junk Movie Like Kochadaiyaan & Will It Survive The Debacle?



I never knew Kochadaiyaan was an animation movie till I saw the trailer and pictures. The quality of the animation is so pathetic that even die-hard Rajni fans (like me) will not be able to digest it. It will be a wonder if Eros Intl is even able to recover its investment of Rs. 150 crore in the film. If you are an Eros’ shareholder, this is your cue to take your money and run

Will Eros International Sink With Salman Khan’s “Jai Ho” Debacle?



The news that the latest Salman Khan movie “Jai Ho” is a dud has sent a chill down the spine of Eros International’s shareholders who have been facing dry returns from the stock since its’ listing

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 493 other subscribers

RSS Stocks Talk Forum

  • Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap)
    Top Picks Basket of 16 Stocks (8 Large-Cap, 5 Mid-Cap & 3 Small-Cap) for Nov '24. The Basket has delivered return of 329% since inception (May’20) vs 162% return delivered by NIFTY Index over the same period due to thematic approach to Top Picks selection Download report
  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!